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OBJECTIVES: An adverse consequence of cancer is venous thromboembolism(VTE),
manifesting as either deep vein thrombosis(DVT) or pulmonary embolism(PE). Com-
pared with non-cancer patients, the incidence of VTE has been increasing in cancer 
patients over the past ten years and the risk of recurrent DVT and subsequent
PE remains elevated. The aim of this study was to assess the cost-effectiveness of 
anticoagulant therapies to prevent VTE in Mexican patients with cancer from the 
payer’s perspective. METHODS: A six-state Markov model was performed to estimate
health and economic consequences during a time horizon of one year (1-week cycles).
Effectiveness measures were reduction in recurrent hospitalizations, reduced PE
and DVT events; and avoidance of deaths. Markov transition probabilities
were obtained from a meta-analysis employing international published literature. 
Comparators employed were warfarin(5 mg/day); dalteparin(2500,5000,7500 IU/
day); enoxaparin(20,40,60 mg/day); nadroparin(5700 IU/day); unfractionated heparin
plus warfarin(10000,30000,42000 IU/day5 mg/day); acenocoumarol(4 mg/day); and
no prophylaxis intervention. Resource use and costs were collected from clinical
records (n  7000) from Social Security Mexican Institute (IMSS) hospitals and ofﬁ cial 
institutional databases. The model was validated. Bootstrapping techniques were used 
to develop probabilistic sensitivity analyses. Acceptability curves were constructed. 
RESULTS: Incidence of PE and DVT were signiﬁ cant lower for patients treated with
dalteparin(p  0.05). Regarding the reduction of DVT events, dalteparin 2500, 5000 
and 7000 IU/day showed an Incremental cost-effectiveness ratio[CI95%] of 
US$45.81[US$44.9–US$46.8]; US$40.9[US$40.0–US$41.7] and US$37.8[US$37.0–
US$38.5] against warfarin (gold-standard), respectively. Nevertheless, enoxaparin 
in all its presentations and no prophylaxis intervention alternatives were dominated
by dalteparin. Dalteparin showed the lowest number of deaths and hospitalization 
re-admissions(for DVT and PE) when compared to other anticoagulant therapies
(p  0.05) and showed a trend toward signiﬁ cant reduction of institutional costs in 
the short term. Second-order Monte Carlo sensitivity analyses showed the robustness
of these results (ellipse-method). CONCLUSIONS: Dalteparin demonstrated to be a 
cost-effective anticoagulant therapy to reduce incidence of PE and DVT events, deaths
and recurrent hospitalizations in patients with cancer.
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COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE 150 MG FOR THE
PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS AGED
OVER 75 YEARS UNDERGOING TOTAL HIP OR KNEE ARTHROPLASTY
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OBJECTIVES: Dabigatran etexilate (DBG) is a new direct thrombin inhibitor which 
is administered orally at a ﬁ xed dose. EMEA has approved DBG at a standard dose
of 220 mg once daily (od), and at a lower dose of 150 mg od for patients aged over 
75. Recent economic analyses for the UK have demonstrated that DBG 220 mg od is 
cost-saving when compared with the commonly used agent, enoxaparin 40 mg od,
with comparable efﬁ cacy and safety. This analysis investigates the cost-effectiveness 
of DBG 150 mg od for the prevention of venous thromboembolism (VTE) in the subset
of patients aged over 75 undergoing total hip arthroplasty (THA) or total knee 
arthroplasty (TKA) from the perspective of the UK National Health Service. 
METHODS: There was a comparison of DBG 150 mg od to enoxaparin 40 mg od 
using a decision model. Relative risks for VTE and bleeding events speciﬁ c to patients 
aged over 75 were derived from sub-group analyses of the phase III DBG trials, RE-
MODEL and RE-NOVATE. Probabilities of recurrent VTE and post-thrombotic syn-
drome were estimated from published longitudinal studies. RESULTS: DBG was less
costly than enoxaparin in TKR and substantially less so in THR, primarily due to 
differences in administration costs. VTE and bleeding rates were similar for DBG and 
enoxaparin; the probability of cost-effectiveness was 89% in TKR and 99% in THR 
at a willingness-to-pay threshold of a20,000 per quality-adjusted life-year. These 
results were robust across a range of sensitivity analyses. CONCLUSIONS: Throm-
boprophylaxis with DBG 150 mg od in patients aged over 75 years is cost saving 
compared to enoxaparin 40 mg od, with comparable efﬁ cacy and safety.
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FROM THE JIKEI HEART STUDY
Shimizu M1, Crawford B2, Ikewaki K1, Taniguchi I1, Kamae I3, Dahlof B4, Drost P5, 
Mochizuki S1
1Jikei University School of Medicine, Tokyo, Tokyo, Japan, 2Mapi Values, Tokyo, Meguro, Japan, 
3Keio University Graduate School of Health Management, Fujisawa, Kanagawa, Japan, 
4Sahlgrenska University Hospital, Gothenburg, Gothenburg, Sweden, 5Mapi Values, AX
Houten, AX Houten, Netherlands
OBJECTIVES: The Jikei Heart Study (n  3081) demonstrated that the angiotensin II 
receptor blocker (ARB) valsartan signiﬁ cantly reduced the incidence of the primary 
composite endpoint in Japanese patients previously receiving standard non-ARB
therapy. The primary end point was a composite of CV morbidity/mortality including
stroke or transient ischemic attack, hospitalization for heart failure or angina, dissect-
ing aneurysm of the aorta, lower-limb arterial obstruction, doubling of serum creati-
nine, and transition to dialysis. The purpose of this study was to determine whether 
valsartan is cost-effective based on data from the Jikei Heart Study. METHODS: A
probabilistic model assessed the cost-effectiveness of valsartan vs. standard therapy in 
a Japanese patient population. Cost-effectiveness analyses incorporated life-years 
gained and quality-adjusted-life-years gained to adjust for impairment of quality-of-
life. Conservative “cost accounting” of the Jikei Heart Study was employed to validate
model results—direct medical costs associated with in- and out-patient treatment of 
patients. A probabilistic sensitivity analysis assessed the robustness of the results. 
RESULTS: Expected total costs for the non-ARB arm were ¥365,961 per patient for 
three years compared to ¥365,151 per patient for three years for valsartan—a cost-
savings of ¥270 per patient per year. Valsartan would also extend quality adjusted life
years (QALY) by 0.09 over non-ARB treatment in the 3-year time horizon. The cost 
savings and increased QALYs lead to a ¥85,215 per QALY gained, a dominant 
strategy. Probabilistic sensitivity analyses demonstrated robustness of the economic 
evaluation. CONCLUSIONS: Valsartan is cost-effective in Japanese patients with high 
blood pressure, coronary heart disease and/or heart failure, who previously received 
standard care. Including costs associated with National Health Insurance sickness 
allowance for extended disability, valsartan is both more effective and less costly than 
non-ARB treatment.
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OBJECTIVES: Dabigatran etexilate (DBG) is a new direct thrombin inhibitor which 
is administered orally at a ﬁ xed dose. Patients with renal impairment are thought to 
be at higher risk of bleeding during thromboprophylaxis, and lower doses are recom-
mended in this population. EMEA has approved DBG at a standard dose of 220 mg 
once daily (od), and at a lower dose of 150 mg od for patients with moderate renal 
impairment. Recent economic analyses for the UK have demonstrated that DBG 
220 mg od is cost-saving when compared with the commonly used agent, enoxaparin
40 mg od, with comparable efﬁ cacy and safety. This analysis investigates the cost-
effectiveness of DBG 150 mg od for the prevention of venous thromboembolism (VTE) 
in patients with moderate renal impairment undergoing total hip arthroplasty (THA)
or total knee arthroplasty (TKA) from the perspective of the UK National Health
Service. METHODS: DBG 150 mg od was compared to enoxaparin 40 mg od using 
a decision model. Relative risks for VTE and bleed events speciﬁ c to patients with 
moderate renal impairment (creatinine clearance q30 and 50 mL/min) were derived 
from sub-group analyses of the phase III DBG trials, RE-MODEL and RE-NOVATE. 
Probabilities of recurrent VTE and post-thrombotic syndrome were estimated from 
published longitudinal studies. RESULTS: DBG was less costly than enoxaparin in
TKR and substantially less so in THR, primarily due to differences in administration 
costs. VTE and bleeding rates were similar for DBG and enoxaparin; the probability
of cost-effectiveness was 75% in TKR and 97% in THR at a willingness-to-pay 
threshold of £20,000 per quality-adjusted life-year. These results were robust across
a range of sensitivity analyses. CONCLUSIONS: Thromboprophylaxis with DBG 
150 mg od in patients with moderate renal impairment is cost saving compared to 
enoxaparin 40 mg od, with comparable efﬁ cacy and safety.
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OBJECTIVES: To perform health economic evaluation of iso-osmolar Iodixanol vs. 
low-osmolar contrast media in patients undergoing coronarography. METHODS: The 
decision tree modeling was performed using literature data on dosage, efﬁ cacy and
safety. Iopromide as one of the commonly used low-osmolar contrast in Russia was 
chosen for comparison. Efﬁ cacy of Iodixanol and Iopromide was equal, so only safety
issues were taken into consideration. Costs of procedure including side effects manage-
ment were calculated using experts interview in Moscow clinics and hospital cost 
estimates. Cost-minimization analysis (CMA) from health care system perspective was 
performed. RESULTS: According to McCullough PA, et al. (2006) the rate of contrast-
induced nephropathy (CIN) was 1.4% for Iodixanol and 3.5% for Iopromide in 
common population, 2.8% and 8.4% in patients with chronic kidney disease (CKD), 
and 3.5% and 15.5% in patients with diabetes mellitus combined with CKD. Rihal 
CS and colleagues (2002) showed that CIN patients required haemodialysis in 7.9%.
They demonstrated 22% mortality compared to 1.4% of patients with normal renal 
function. Hypotension rate was 20.1% and 9.1%, acute heart failure was 11.4%
and 3.1%, cardiac arrest was 11.4% and 1.5%, respiratory distress-syndrome 
was 9.4% and 0.7%, and myocardial infarction was 3.9% and 0.9% respectively.
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The cost savings following the use of Iodixanol compared to Iopromide in coronar-
ography averaged 2287 RUB (72 USD) in common population, 2866 RUB (USD91) 
in patients with CKD, and 3427 RUB (US$109) in patients with diabetes mellitus and
CKD. CONCLUSIONS: The results of this study demonstrated Iodixanol to be cost-
saving compared to low-osmolar contrast media both in risk groups and in general
population.
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OBJECTIVES: The Take Control of Your Blood Pressure trial randomized 636 com-
munity-dwelling individuals with hypertension to evaluate the impact of a telephonic 
behavioral self-management intervention, home blood pressure monitoring, and both 
interventions combined compared to usual care on reducing systolic blood pressure 
(SBP) over 24 months. At 24 months, the combined intervention demonstrated a sig-
niﬁ cant 3.9 mmHg (95%CI: 0.9,6.9) reduction in SBP relative to usual care. Patients
randomized to home BP monitoring or the behavioral intervention had less improve-
ment (0.6 mmHg and 0.6 mmHg, respectively). A prospective economic evaluation 
was performed. METHODS: Measures of medical resource use costs were derived 
from electronic data representing medical care delivered within the Duke University 
Health System. Intervention-related costs, including patient time, were estimated using 
patient-level data collected during the trial, administrative records, and published unit
costs. Sensitivity analyses were conducted to evaluate the impact of changing assump-
tions about overhead costs and time between completed phone encounters when esti-
mating costs associated with the behavioral intervention. RESULTS: On average, over 
24 months, patients incurred $6,965 (SD  22,054) in inpatient costs and $8,676 (SD 
 9,368) in outpatient costs, with no signiﬁ cant differences across intervention groups. 
When applying base-case assumptions, 24-month intervention costs were estimated to
be $90 (SD  2) for home blood pressure monitoring, $345 (SD  64) for the behav-
ioral intervention ($31 per phone encounter) and $416 (SD  93) for the combined
intervention. In sensitivity analyses, the cost for each phone encounter ranged from
approximately $10 to $45. Patient time costs were estimated at $585 (SD  487) for
home monitoring, $55 (SD  16) for the behavioral intervention and $741 (SD  529) 
for the combined intervention. CONCLUSIONS: Home blood pressure monitoring 
and/or the behavioral intervention had little impact on medical resource use or costs
over 2 years. Our analysis demonstrated that these interventions are cost-additive to 
the health care system and that patients’ time costs are considerable.
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ECONOMIC ANALYSIS OF THE ENDEAVOR DRUG-ELUTING STENT VS. 
THE DRIVER BARE METAL STENT: RESULTS FROM THE ENDEAVOR II
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OBJECTIVES: To assessed the economic attractiveness of the Endeavor drug-eluting 
stent (DES) vs. the Driver bare metal stent (BMS) using 4-year follow-up information 
from the ENDEAVOR II clinical trial. METHODS: We used clinical, index procedure
and follow-up events data from subjects randomized to receive Endeavor (n  598)
vs. Driver (n  599), and applied Medicare cost and quality of life adjustments from
secondary sources. We compared differences in clinical endpoints, medical costs, and
quality adjusted survival through 4 years follow-up (1440 days). RESULTS: Patients
in both treatment groups had similar baseline characteristics. The use of Endeavor vs.
Driver reduced 4-year target vessel revascularization (TVR) rates per 100 subjects
(10.4 vs. 21.5; difference, 11.1; 95% conﬁ dence interval [CI], 16.0 to 6.1; p 
.001), with no difference in the rates per 100 subjects of death (5.0 vs. 5.2; difference, 
.2; 95% CI, 2.4 to 2.7; p  .90) or non-fatal myocardial infarction (MI) (3.2 vs. 
4.4; difference, 1.2; 95% CI, 3.4 to 1.0; p  .29). After discounting at a 3% annual 
rate, there were no differences in quality-adjusted survival days (1093 vs. 1090; dif-
ference, 3; 95% CI, 13 to 19; p  .69) and total medical costs ($21,483 vs. $21,680; 
difference, $198; 95% CI, $1608 to $1207, p  .78). CONCLUSIONS: The use of 
Endeavor vs. Driver was associated with a signiﬁ cant reduction in TVR through four
years follow-up with no difference in death, non-fatal MI, quality-adjusted survival,
or total medical costs. These results are comparable to those for other studies compar-
ing DES vs. BMS.
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OBJECTIVES: To evaluate the economic attractiveness of Endeavor vs. Cypher drug-
eluting stents (DES) in the ENDEAVOR III clinical trial. METHODS: We analyzed 
case report form information from subjects randomized to receive Endeavor (n  323)
vs. Cypher (n  113) stents, using quality of life adjustment and Medicare cost weights 
applied from secondary sources, and a $2100 cost for stents. We compared differences 
in outcomes and costs; and evaluated cost-effectiveness through 3-years follow-up
(1080 days). RESULTS: The use of Endeavor vs. Cypher stents reduced the 3-year
rates per 100 subjects of death or myocardial infarction (MI) (3.9 vs. 10.8; difference,
6.9; 95% conﬁ dence interval [CI], 0.8 to 9.9; p  .028), with no difference in 
target vessel revascularization rates (17.9 vs. 12.2; difference, 5.7; 95% CI, 3.9 to 
15.1; p  .23), but greater use of coronary artery bypass graft surgery (3.5 vs. 0.0;
difference 3.5; 95% CI, 1.3 to 5.7; p  .002). After discounting at 3% per annum, 
total medical costs for Endeavor vs. Cypher were similar ($23,353 vs. $21,657; dif-
ference, $1696; 95% CI, $1089 to $4482, p  .23), and the 3-year cost-effectiveness 
ratio was $57,002 per quality-adjusted life year. CONCLUSIONS: Use of Endeavor 
vs. Cypher led to reductions in death or MI, with no differences in other outcomes.
These ﬁ ndings are unexpected in DES comparisons. If future trials observe similar 
differences, the use of Endeavor vs. Cypher will be economically attractive by conven-
tional standards.
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MEDICAL EXPENDITURES ATTRIBUTABLE TO CORONARY ARTERY
DISEASE IN THE UNITED STATES
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OBJECTIVES: This study estimated medical expenditures attributable to coronary 
artery disease (CAD) in the US and investigated CAD case deﬁ nition in a nationally
representative sample. METHODS: Data from 2005 from the nationally representa-
tive Medical Expenditure Panel Survey (MEPS) were used to estimate the population 
with CAD and their medical expenditures. CAD cases were identiﬁ ed by patient-
reported myocardial infarction (MI), angina pectoris and/or coronary heart disease 
(CHD). Case deﬁ nition analysis used multivariable logistic regression. Person-level and
national expenditures were estimated on a logarithmic scale using a maximum 
likelihood Heckman selection model and Smearing re-transformation. All analyses 
employed Taylor series linearization methods to account for the complex survey design 
and adjusted for age, race, ethnicity, gender, income, education, and overweight status. 
RESULTS: In the 2005 civilian noninstitutionalized adult population (n  22262), 
there were 1016 CAD cases using a strict deﬁ nition of either MI or angina and 1266 
cases using a broad deﬁ nition including patient-reported CHD. Of those reporting
CHD (n  702), only 65% (n  458) had MI or angina . Females and blacks reporting
CHD were less likely to have MI or angina (OR  0.52, 0.39, p  0.01). Annual direct 
medical expenditures attributable to strictly deﬁ ned CAD were estimated to be $6456
($2007), on average, per person. Expenditures for broadly deﬁ ned CAD were $6453 
($2007). Based on this estimate and the weighted estimate of persons with CAD 
(approximately 9.8 million), the projected annual US medical expenditures attribut-
able to CAD are $63 billion ($2007). CONCLUSIONS: While CAD and CHD are
generally diagnosed by either MI or angina, patient-reported CHD is not consistent 
with this deﬁ nition. Consistency appears to vary with gender and race. While the CAD 
case deﬁ nition varies, expenditures do not. Results of this study indicate that direct 
medical expenditures associated with CAD in the US are substantial.
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IDENTIFYING DRIVERS OF POST-HOSPITAL DISCHARGE FOR PATIENTS 
WITH ACUTE CORONARY SYNDROME (ACS) USING QUANTILE
REGRESSIONS
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OBJECTIVES: To identify drivers of post-hospital costs among ACS patients, includ-
ing treatment type received. Patients who are hospitalized with ACS have different 
treatment options, including revascularization procedures. While these procedures 
are expensive, there might be offsets in future health care costs by preventing 
adverse coronary events. METHODS: We studied commercially insured individuals, 
aged 18–64, with 36 months continuous enrollment in a large, geographically diverse 
health plan between January 2003 and December 2006. Patients were identiﬁ ed if 
they were hospitalized between January 1, 2004 and December 31, 2005 with a
diagnosis of ACS. A 1 year follow-up period was used and costs incurred after 
patients’ initial hospital discharge were examined. In addition to ordinary least squares
(OLS),, quantile-regression models (QRM) were used to identify drivers of post-
hospital costs. QRM make no assumption about the distribution of the error term
and provide quantile-speciﬁ c covariate effects, which is useful in applications with 
highly skewed data. RESULTS: OLS results indicated co-morbidity scores, prior 
health care costs and initial hospital diagnosis were main drivers of post-hospital 
discharge costs (p  0.01). Also, revascularization procedures during the initial 
hospitalization were not signiﬁ cantly associated with post-hospital costs. QRM con-
ﬁ rmed the other ﬁ ndings but showed, at the lower end of the post-hospital costs dis-
tribution, having revascularization procedures during the initial hospitalization was
signiﬁ cantly associated with higher post-hospital costs. This effect was not signiﬁ cant 
in the upper quantiles. CONCLUSIONS: In this study, initial hospital diagnosis, higher
co-morbidity scores and prior health care costs were associated with higher post-
hospital costs. Also, QRM showed revascularization procedures were drivers of cost 
for patients with lower post-hospital expenditures. This is an intuitive ﬁ nding con-
sidering patients who have revascularization procedures may have more follow-up 
care compared to those without revascularization. However, these patients may have
fewer secondary events requiring hospitalization, thus keeping them in the lower cost
quantiles.
